According to Psychiatric News (5/9), in a May 4 news release, the FDA announced it has “cleared for marketing the first biomarker-based diagnostic test for Alzheimer’s disease.” The test, called “the Lumipulse G β-Amyloid Ratio (1-42/1-40) test” and “manufactured by Fugirebio Diagnostics Inc., measures two variants of the amyloid beta protein in cerebrospinal fluid.” A positive test “result suggests that a patient may have amyloid plaques in the brain associated with Alzheimer’s disease.” This “test is intended for use in adults aged 55 years and older with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.” (SOURCE: APA Headlines)